Eli Lilly and Company (NYSE:LLY) Stock Sale Disclosed by Rep. Michael A. Rulli

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rep. Michael A. Rulli disclosed selling $1,001–$15,000 of Eli Lilly shares on November 4 from a Merrill Lynch managed account.
  • Eli Lilly reported quarterly EPS of $7.48, beating the $5.71 consensus, while revenue rose 38.6% year over year to $24.4 billion.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $1,422; the company also declared a quarterly dividend of $1.73 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 4th. The trade occurred in the Representative's "MERRILL LYNCH SIMPLE MANAGED ACCOUNT" account.

Representative Michael A. Rulli also recently made the following trade(s):

  • Sold $1,001 - $15,000 in shares of Costco Wholesale NASDAQ: COST on 11/12/2026.
  • Sold $1,001 - $15,000 in shares of Lumentum NASDAQ: LITE on 11/4/2026.
  • Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 11/4/2026.
  • Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 11/4/2026.
  • Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 10/28/2026.
  • Sold $50,001 - $100,000 in shares of Alphabet NASDAQ: GOOG on 10/16/2026.
  • Sold $1,001 - $15,000 in shares of WesBanco NASDAQ: WSBC on 10/16/2026.
  • Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 9/28/2026.
  • Sold $1,001 - $15,000 in shares of Wells Fargo & Company NYSE: WFC on 9/3/2026.
  • Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 9/3/2026.

Eli Lilly and Company Trading Down 2.2%

Shares of LLY opened at $1,352.18 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market cap of $1.27 trillion, a price-to-earnings ratio of 43.28, a PEG ratio of 1.65 and a beta of 0.40. The stock has a fifty day moving average price of $1,263.45 and a two-hundred day moving average price of $1,117.53. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 earnings per share. The business's revenue for the quarter was up 38.6% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's payout ratio is presently 22.46%.

Trending Headlines about Eli Lilly and Company

Here are a few of the latest headlines about LLY:

  • Positive Sentiment: Lilly is broadening its pipeline beyond obesity drugs, including oncology acquisitions and collaborations, while analysts have pointed to immunology as a possible future growth driver. These moves may diversify growth over time, though the programs are at varying stages of development. Eli Lilly expands its oncology research platform Is immunology emerging as Eli Lilly’s next growth driver?
  • Neutral Sentiment: Lilly’s 2026 acquisition spending has surpassed $32 billion, including deals aimed at building cancer and immunology capabilities. The investments could strengthen future growth but also raise execution and capital-allocation questions. Lilly buying spree surpasses $32 billion
  • Negative Sentiment: A report that Lilly stopped highlighting dose counts prompted questions about what the change signals for demand and disclosure, adding uncertainty around its obesity-drug growth story. Separately, State Street’s health-care ETF sold $42.3 million of Lilly shares, a potential source of near-term selling pressure. Eli Lilly stopped touting dose counts. Should you worry?

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JDM Financial Group LLC grew its stake in shares of Eli Lilly and Company by 66.7% during the 3rd quarter. JDM Financial Group LLC now owns 25 shares of the company's stock worth $29,000 after acquiring an additional 10 shares in the last quarter. Torren Management LLC raised its holdings in shares of Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company's stock valued at $37,000 after purchasing an additional 25 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $42,000. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the third quarter worth $49,000. Finally, Sumitomo Mitsui Financial Group Inc. lifted its position in shares of Eli Lilly and Company by 5,100.0% in the third quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company's stock worth $60,000 after purchasing an additional 51 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company's stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. HSBC increased their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a report on Thursday, September 10th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 21st. Argus upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. Bank of America reissued a "buy" rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. Finally, Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a "buy" rating in a research report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1,422.00.

Get Our Latest Analysis on LLY

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio's 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027. Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio's 6th Congressional District. He declared candidacy for the 2026 election. Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli's career experience includes working as the director of operations with Rulli Bros. Markets.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines